FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

CTATEMENIT	OF CHANCES	IN DENETICIAL	OWNEDCHID
SIAIEMENI	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ELMS STEVE					2. Issuer Name and Ticker or Trading Symbol ADMA BIOLOGICS, INC. [ADMA]						(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner			
(Last) (First) (Middle) 888 SEVENTH AVE 30TH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 01/30/2015								(give title	Other (below)	specify
(Street) NEW Y(ORK N		10106 Zip)	4.	f Amei	ndment,	Date	of Original Fil	ed (Month/C	ay/Year)	Lin	e) X Form	filed by One F	Filing (Check Ap Reporting Perso than One Repo	on
			le I - Non-D	erivativ	e Sec	curities	s Ac	quired, D	isposed (of, or Be	neficial	lly Owned			
1. Title of Security (Instr. 3) 2. Transac Date			Transaction ate onth/Day/Ye	Execution Date,		Code (Instr. 5)		ed (A) or str. 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	Amount	(A) o (D)	Price	Transac (Instr. 3	tion(s)		(1130.4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	Conversion Da	Date Execution (Month/Day/Year) if any	3A. Deemed Execution Datif any (Month/Day/Ye	Date, Transacti Code (Ins				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Options to purchase	\$10.8 ⁽¹⁾	01/30/2015		A		9,000		(2)	01/30/2025	Common Stock	9,000	\$0	9,000	D ⁽³⁾	

- 1. The exercise price reflects the per share fair market value of the Company's common stock, as determined by the closing price of the Company's common stock on the NASADAQ Stock Market on January 30, 2015, the date that the option grant was approved by the Company's board of directors.
- 2. These options will vest monthly over a period of 24 months and terminate 12 months following separation.
- 3. These stock options are held by Mr. Elms for the benefit of Aisling Capital LLC. Mr. Elms disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

02/03/2015 /s/ Steve Elms

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.